Growth Hormone Axis & Peptides

The growth hormone axis is a three-tier endocrine cascade: hypothalamus, anterior pituitary, and liver/peripheral tissues. Rather than a simple on-off switch, it operates as an integrated oscillatory system -- the hypothalamus sets the rhythm, the pituitary amplifies the signal, and the liver converts it into sustained anabolic output through IGF-1. This architecture explains why peptide secretagogues can restore GH signaling more physiologically than exogenous GH replacement.

Hypothalamic control: the push-pull oscillator

Two hypothalamic neuron populations govern GH secretion through opposing signals. GHRH (growth hormone-releasing hormone), a 44-amino-acid peptide from arcuate nucleus neurons, provides the stimulatory drive. Somatostatin (SST/SRIF), a 14-amino-acid peptide from the periventricular nucleus, provides the inhibitory brake.

These signals alternate in a push-pull oscillator pattern: GHRH release rises while somatostatin tone falls, producing a GH pulse; then somatostatin increases and GHRH drops, creating the trough. This rhythmic alternation generates pulsatile GH secretion with a major pulse roughly every 2-3 hours.

A third input -- ghrelin, a 28-amino-acid acylated peptide from gastric oxyntic cells -- adds a nutritional dimension. Ghrelin acts both on the hypothalamus and directly on pituitary somatotrophs through GHS-R1a. Its secretion rises with fasting and falls after meals. The convergence of GHRH, somatostatin withdrawal, and ghrelin drives the large GH pulses during overnight fasting and slow-wave sleep.

Pituitary GH release: somatotroph integration

Somatotroph cells constitute roughly 50% of anterior pituitary hormone-producing cells. They express two receptor systems that integrate the signals described above.

The GHRH receptor (Class B GPCR) signals through Gs/cAMP/PKA. GHRH binding activates adenylyl cyclase, raises intracellular cAMP, and stimulates both GH gene transcription and vesicular exocytosis. This is the primary driver of GH synthesis.

The GH secretagogue receptor (GHS-R1a) / ghrelin receptor (Class A GPCR) signals through Gq/PLC/IP3/calcium. Activation raises intracellular calcium, directly triggering GH vesicle release. Because these two pathways converge on the same somatotroph but use different second messenger cascades, simultaneous activation produces synergistic -- not merely additive -- GH release.

The secretion pattern features a large nocturnal pulse during slow-wave sleep (roughly 70% of daily output), with smaller daytime pulses triggered by exercise, fasting, or stress. Total daily GH secretion peaks during puberty and declines steadily thereafter. By the sixth decade, output falls to roughly 25% of peak levels -- a phenomenon termed somatopause, reflecting reduced GHRH drive, increased somatostatin tone, and diminished somatotroph mass.

Hepatic IGF-1 production: the effector arm

Circulating GH binds the GH receptor (GHR) on hepatocytes -- a single-pass transmembrane receptor signaling through JAK2/STAT5. GH induces GHR dimerization, activates JAK2 tyrosine kinase, and phosphorylates STAT5b, which translocates to the nucleus and drives transcription of IGF-1, IGFBP-3, and ALS (acid-labile subunit).

IGF-1 is the primary downstream effector of GH. In circulation, over 95% is sequestered in a ternary complex of IGF-1, IGFBP-3, and ALS. This complex extends IGF-1 half-life from roughly 10 minutes (free) to 12-16 hours (bound), creating a stable reservoir that buffers against pulsatile GH secretion. Free IGF-1 -- the biologically active fraction -- mediates anabolic signaling through the IGF-1 receptor (a receptor tyrosine kinase activating PI3K/Akt and MAPK/ERK pathways).

Beyond hepatic (endocrine) IGF-1, most tissues produce IGF-1 locally in response to GH. This autocrine/paracrine IGF-1 is particularly important in muscle, bone, and cartilage, where local concentrations exceed circulating levels.

Feedback loops: maintaining homeostasis

The axis self-regulates through multiple feedback circuits. IGF-1 long-loop feedback is dominant: circulating IGF-1 stimulates hypothalamic somatostatin release, suppresses GHRH, and directly reduces pituitary GH responsiveness. GH short-loop feedback operates independently -- GH itself stimulates somatostatin neurons, providing rapid braking after each pulse.

The free-to-bound IGF-1 ratio adds further regulation. Only free IGF-1 drives feedback inhibition, so conditions altering IGFBP-3 or ALS (malnutrition, liver disease, insulin status) can shift axis activity without changing total IGF-1. This is why total IGF-1 alone does not always reflect true axis output.

Peptide secretagogues and the axis

Peptide-based GH secretagogues modulate the axis at defined pharmacological entry points while preserving the endogenous feedback architecture.

GHRH analogs act at Tier 1. Sermorelin (GHRH 1-29) mimics native GHRH but has a short half-life (~10-20 minutes). Tesamorelin, approved for HIV-associated lipodystrophy, offers improved pharmacokinetics. CJC-1295 conjugated with a Drug Affinity Complex (DAC) enables albumin binding, extending half-life to roughly 8 days -- sustaining GHRH receptor activation while endogenous somatostatin retains pulsatile modulation.

GHS-R1a agonists act at the ghrelin receptor. Ipamorelin is the most selective, producing GH release without significant cortisol or prolactin co-stimulation. GHRP-2 and GHRP-6 are more potent but less selective. MK-677 (ibutamoren) is a non-peptide, orally bioavailable GHS-R1a agonist providing sustained activation over 24 hours.

Combination protocols (GHRH analog plus GHRP) exploit cAMP/calcium synergy in somatotrophs. Co-administration produces GH pulses substantially larger than either agent alone -- the pharmacological rationale behind the CJC-1295 plus ipamorelin combination.

Clinical relevance

The axis framework explains several clinical phenomena. In adult GH deficiency (whether from pituitary disease or age-related somatopause), secretagogues can restore physiological GH pulsatility -- but only when functional somatotrophs remain. This stands in contrast to exogenous GH, which delivers a non-pulsatile bolus, suppresses endogenous GHRH/GH feedback, and produces sustained IGF-1 elevation rather than the oscillating free-IGF-1 profile seen in healthy physiology. The preservation of pulsatility and feedback is the central rationale for secretagogue-based approaches to age-related GH decline and body composition deterioration.